An analysis of differential coding patterns between Medicare Advantage (MA) and Traditional Medicare (TM) plans estimated how much coding differs between insurers and how much extra revenue insurers ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

The effect of glucagon-like peptide 1 receptor agonists on patients with joint infections was a popular topic at the American ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...

A recent analysis of data from the SELECT trial of semaglutide in overweight or obese patients found that the cardiovascular benefits of the drug seemed to accrue regardless of how much weight ...

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

The list of benefits for Novo Nordisk's semaglutide keeps getting longer ... City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), compared to an 8.7 reduction with placebo.

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

Patients who received preoperative semaglutide had lower postoperative total weight loss at 12 months compared with controls. Median HbA1c levels and diabetes remission at 1 year were similar ...